KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Inventory (2018 - 2025)

Rigel Pharmaceuticals has reported Inventory over the past 8 years, most recently at $11.5 million for Q4 2025.

  • Quarterly results put Inventory at $11.5 million for Q4 2025, up 91.7% from a year ago — trailing twelve months through Dec 2025 was $11.5 million (up 91.7% YoY), and the annual figure for FY2025 was $11.5 million, up 91.7%.
  • Inventory for Q4 2025 was $11.5 million at Rigel Pharmaceuticals, down from $13.3 million in the prior quarter.
  • Over the last five years, Inventory for RIGL hit a ceiling of $13.3 million in Q3 2025 and a floor of $4.7 million in Q1 2025.
  • Median Inventory over the past 5 years was $6.9 million (2021), compared with a mean of $7.8 million.
  • Biggest five-year swings in Inventory: skyrocketed 328.3% in 2021 and later crashed 40.61% in 2024.
  • Rigel Pharmaceuticals' Inventory stood at $6.6 million in 2021, then skyrocketed by 37.82% to $9.1 million in 2022, then tumbled by 39.44% to $5.5 million in 2023, then rose by 8.69% to $6.0 million in 2024, then surged by 91.7% to $11.5 million in 2025.
  • The last three reported values for Inventory were $11.5 million (Q4 2025), $13.3 million (Q3 2025), and $10.4 million (Q2 2025) per Business Quant data.